Uridine Triacetate

CHEMBL2107381 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
370.3 g/mol
LogP
-0.5
Phase
4

Uridine triacetate is a prodrug that is cleaved in vivo to release uridine, which competitively inhibits the incorporation of fluorouracil (5-FU) metabolites into RNA and DNA, thereby rescuing normal cells from 5-FU toxicity. It is used as an antidote for 5-FU overdose or early-onset severe toxicity from 5-FU or capecitabine chemotherapy, and is also approved for hereditary orotic aciduria, a rare enzyme deficiency causing abnormal pyrimidine metabolism. Its mechanism of flooding the uridine pool reduces the relative incorporation of toxic 5-FU metabolites.

น้ำหนักโมเลกุล

370.3100 g/mol

LogP

-0.50

TPSA

138.00 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Counteracts the effects of a specific toxin or drug overdose through competitive antagonism, enhanced elimination, or direct chemical neutralization.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Counteracts the effects of a specific toxin or drug overdose through competitive antagonism, enhanced elimination, or direct chemical neutralization.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O

InChI

InChI=1S/C15H18N2O9/c1-7(18)23-6-10-12(24-8(2)19)13(25-9(3)20)14(26-10)17-5-4-11(21)16-15(17)22/h4-5,10,12-14H,6H2,1-3H3,(H,16,21,22)/t10-,12-,13-,14-/m1/s1

Molecular Formula

C15H18N2O9

HBD / HBA

1 / 9

พันธะที่หมุนได้

8

อะตอมหนัก

26

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Uridine triacetate is a prodrug that is cleaved in vivo to release uridine, which competitively inhibits the incorporation of fluorouracil (5-FU) metabolites into RNA and DNA, thereby rescuing normal cells from 5-FU toxicity. It is used as an antidote for 5-FU overdose or early-onset severe toxicity from 5-FU or capecitabine chemotherapy, and is also approved for hereditary orotic aciduria, a rare enzyme deficiency causing abnormal pyrimidine metabolism. Its mechanism of flooding the uridine pool reduces the relative incorporation of toxic …

Counteracts the effects of a specific toxin or drug overdose through competitive antagonism, enhanced elimination, or direct chemical neutralization.

Yes, Uridine Triacetate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107381. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 20058. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.